GGrantIndex
← Leaderboards

Johnny Huard

Children'S Hosp Pittsburgh/Upmc Hlth Sys

Google Scholar ↗PubMed ↗ORCID ↗
$7,923,168
Attributed
$10,933,386
Total exposure
15
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1M · FY2008–24
$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$10,933,386 · 15

By mechanism

R21$3,387,659 · 9
R01$2,942,417 · 2
UH3$2,563,053 · 1
P01$1,333,688 · 1
UG3$522,288 · 1
U54$184,281 · 1

Top collaborators

Others in their field

Top investigators on “Stem Cells”

Research focus

Stem CellsTissuesCellsNatural RegenerationMuscleInjuryRepairedIn VitroRegenerativeBaseTransplantationReportingPreventDefectResearch StudyLaboratoriesMouse ModelArticular CartilageAdultIn VivoTechnologyAdult Stem CellHealingSkeletal Muscle Structure

Grant awards (40)

The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$551,586
UH3 · FY2024 · AR · contact PI
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$600,051
UH3 · FY2023 · AR · contact PI
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair$155,115
R21 · FY2023 · AR · contact PI
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$621,091
UH3 · FY2022 · AR · contact PI
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair$220,903
R21 · FY2022 · AR · contact PI
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$633,825
UH3 · FY2021 · AR · contact PI
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$156,500
UH3 · FY2021 · AR · contact PI
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis$522,288
UG3 · FY2020 · AR · contact PI
Ablation of Non-Myogenic Progenitor Cells as a New Therapeutic Approach to Duchenne Muscular Dystrophy$149,234
R21 · FY2020 · AR
Development of biological approaches to enhance skeletal muscle rehabilitation after anterior cruciate ligament injury$143,688
R21 · FY2020 · AR
Muscle Stem Cells Reprogrammed Through Genome Engineering for Autonomously Regulated Anti-Fibrotic Therapy$204,154
R21 · FY2019 · AR · contact PI
Ablation of Non-Myogenic Progenitor Cells as a New Therapeutic Approach to Duchenne Muscular Dystrophy$193,864
R21 · FY2019 · AR
Development of biological approaches to enhance skeletal muscle rehabilitation after anterior cruciate ligament injury$188,540
R21 · FY2019 · AR
Effects of Circulating Factors and Progenitors on Wound Healing during Pregnancy$172,150
R21 · FY2019 · AR · contact PI
Bone Abmormalities and Healing Defect in Muscular Dystrophy$344,300
R01 · FY2018 · AR · contact PI
Muscle Stem Cells reprogrammed Through Genome Engineering for Autonomously Regulated Anti-Fibrotic Therapy$211,788
R21 · FY2018 · AR · contact PI
Effects of Circulating Factors and Progenitors on Wound Healing during Pregnancy$203,280
R21 · FY2018 · AR · contact PI
Bone Abnormalities & Healing Defect in Muscular Dystrophy$338,800
R01 · FY2017 · AR · contact PI
CELL AUTONOMOUS AND NON-AUTONOMOUS MECHANISMS OF STEM CELL DEFECTS WITH AGING$264,384
P01 · FY2017 · AG · contact PI
Bone Abnormalities & Healing Defect in Muscular Dystrophy$338,800
R01 · FY2016 · AR · contact PI
CELL AUTONOMOUS AND NON-AUTONOMOUS MECHANISMS OF STEM CELL DEFECTS WITH AGING$264,384
P01 · FY2016 · AG · contact PI
Bone Abnormalities & Healing Defect in Muscular Dystrophy$338,800
R01 · FY2015 · AR · contact PI
CELL AUTONOMOUS AND NON-AUTONOMOUS MECHANISMS OF STEM CELL DEFECTS WITH AGING$256,451
P01 · FY2015 · AG · contact PI
Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair$185,196
R21 · FY2015 · EB · contact PI
The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeleta$178,488
R21 · FY2015 · AR · contact PI
Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair$48,228
R21 · FY2015 · EB · contact PI
The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeleta$24,792
R21 · FY2015 · AR · contact PI
Bone Abnormalities & Healing Defect in Muscular Dystrophy$337,975
R01 · FY2014 · AR · contact PI
CELL AUTONOMOUS AND NON-AUTONOMOUS MECHANISMS OF STEM CELL DEFECTS WITH AGING$264,384
P01 · FY2014 · AG · contact PI
Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair$194,330
R21 · FY2014 · EB · contact PI
The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeleta$168,988
R21 · FY2014 · AR · contact PI
CELL AUTONOMOUS AND NON-AUTONOMOUS MECHANISMS OF STEM CELL DEFECTS WITH AGING$284,085
P01 · FY2013 · AG · contact PI
Nerve Repair through Muscle Progenitor Cell Transplantation$219,296
R21 · FY2013 · NS · contact PI
Nerve Repair through Muscle Progenitor Cell Transplantation$189,375
R21 · FY2012 · NS · contact PI
Muscle-based tissue engineering to improve bone healing$454,500
R01 · FY2010 · DE · contact PI
Muscle stem cell therapy in a mouse model of premature aging$183,610
R21 · FY2010 · AG · contact PI
Muscle-based tissue engineering to improve bone healing$454,500
R01 · FY2009 · DE · contact PI
Muscle stem cell therapy in a mouse model of premature aging$152,640
R21 · FY2009 · AG · contact PI
Muscle-based Tissue Engineering to Improve Bone Healing$334,742
R01 · FY2008 · DE · contact PI
Muscle Stem Cell-based therapies for Cardiomyopathy$184,281
U54 · FY2008 · AR · contact PI